Form 4: PharmaCyte CEO Silverman Reports Stock Transactions

PharmaCyte Biotech's CEO and President, Joshua Silverman, reported the acquisition of 575,000 shares and the disposition of 258,750 shares for tax purposes.

Summary

• Joshua Silverman, CEO and President of PharmaCyte Biotech, Inc. (PMCB), reported changes in his beneficial ownership.
• He acquired 575,000 shares of common stock on December 12, 2025, at a price of $0.
• He disposed of 258,750 shares of common stock on the same date at a price of $1.02.
• The disposition represents shares withheld by the Issuer to satisfy tax liability upon the vesting of restricted stock units and does not constitute an actual sale or other open-market transaction.
• Following these transactions, Silverman directly owns 316,250 shares and indirectly owns 50,000 shares through JNS Holdings Group LLC.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The acquisition of shares (via RSU vesting) indicates continued equity compensation and alignment of interests, while the disposition is a standard tax-related event, not a discretionary sale.

Positives

• The acquisition of 575,000 shares at a $0 price indicates the vesting of restricted stock units, which is a form of equity compensation and aligns management's interests with shareholders.

Negatives

• The disposition of 258,750 shares, even for tax purposes, reduces the direct share count beneficially owned by the CEO.

Future Outlook

NA

Industry Context

This Form 4 filing is a routine disclosure of insider stock transactions, common across all publicly traded companies. It reflects compensation events (RSU vesting) and associated tax withholdings, rather than discretionary open-market purchases or sales, which are typical for executives in the biotech sector.

Related Party Transactions

• The disposition of 258,750 shares represents shares withheld by PharmaCyte Biotech, Inc. (the Issuer) to satisfy tax liability upon the vesting of restricted stock units, which is a transaction between the reporting person and the company.

Stakeholder Impact

• Shareholders: Provides transparency into executive stock ownership and compensation. The net increase in directly owned shares (after tax withholding) from the RSU vesting could be seen as a positive signal of management's continued stake in the company's performance.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving the vesting of restricted stock units and the subsequent withholding of shares for tax purposes. It does not indicate a discretionary open-market purchase or sale by the CEO that would suggest a strong change in sentiment or fundamental outlook for the company. Therefore, it provides no new information to alter an existing investment thesis, warranting a 'hold' recommendation based solely on this filing.

Keywords

PharmaCyte Biotech, PMCB, Joshua Silverman, Insider Trading, Form 4, Stock Ownership, Restricted Stock Units, CEO, Director